Zacks Research Decreases Earnings Estimates for OPKO Health

OPKO Health, Inc. (NASDAQ:OPK) – Equities research analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for OPKO Health in a research note issued to investors on Wednesday, May 21st. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings of ($0.09) per share for the quarter, down from their previous forecast of ($0.07). The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. Zacks Research also issued estimates for OPKO Health’s Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.37) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.11) EPS.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $149.90 million during the quarter, compared to the consensus estimate of $163.13 million. During the same quarter in the previous year, the firm earned ($0.12) earnings per share. The business’s quarterly revenue was down 13.7% compared to the same quarter last year.

Several other equities analysts have also commented on OPK. Barrington Research reiterated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Thursday, May 1st. JPMorgan Chase & Co. began coverage on OPKO Health in a research note on Friday, April 25th. They set a “neutral” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Monday, April 7th. Finally, Wall Street Zen cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $2.75.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.26 on Monday. The firm has a market capitalization of $999.25 million, a P/E ratio of -6.63 and a beta of 1.42. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The stock’s 50-day simple moving average is $1.46 and its two-hundred day simple moving average is $1.55. OPKO Health has a twelve month low of $1.19 and a twelve month high of $2.04.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $1.74 per share, for a total transaction of $348,000.00. Following the acquisition, the chief executive officer now owns 213,501,448 shares in the company, valued at $371,492,519.52. This represents a 0.09% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders acquired 767,434 shares of company stock worth $1,238,312. 49.69% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On OPKO Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC raised its position in shares of OPKO Health by 68.7% in the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company’s stock worth $1,347,000 after acquiring an additional 373,032 shares in the last quarter. Norges Bank bought a new position in shares of OPKO Health in the 4th quarter worth approximately $1,657,000. Price T Rowe Associates Inc. MD raised its position in shares of OPKO Health by 4.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock worth $670,000 after acquiring an additional 18,571 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of OPKO Health by 14.9% in the 4th quarter. Wells Fargo & Company MN now owns 229,262 shares of the biotechnology company’s stock worth $337,000 after acquiring an additional 29,738 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of OPKO Health in the 4th quarter worth approximately $221,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.